EIKN — Eikon Therapeutics, Inc. Common Stock
$7.26-11.89%
Last close: · regular session
Last 60 sessions
EIKN closed at $7.26 (-11.89%) on Oct 23, 2026. Float: 31.1M shares. Latest SEC filing: 8-K on Oct 26, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for EIKN in the TickerWise workspace.
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops innovative medicines to address serious unmet medical needs. It develops a platform that permits precise characterization of protein interactions in living cells. Its products includes EIK1001 is a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004 are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004, to address brain metastases and primary brain malignancies; EIK1005 a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006. The company was incorporated in 2019 and is based in Millbrae, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Website: https://eikontx.com
Latest SEC filings for EIKN
Latest EIKN news
- Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress Read article
- Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.